U.S. Markets open in 9 hrs 15 mins

Dynavax Technologies Corporation (DVAX)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
10.00-0.35 (-3.38%)
At close: 4:00PM EDT
People also watch
NVAXACADARRYFOLDBCRX

Dynavax Technologies Corporation

2929 Seventh Street
Suite 100
Berkeley, CA 94710
United States
510-848-5100
http://www.dynavax.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees251

Key Executives

NameTitlePayExercisedAge
Mr. Eddie GrayChief Exec. Officer and Director602kN/A58
Dr. Dennis A. Carson Ph.D., M.D.Co-Founder and Director40kN/A70
Mr. Michael S. Ostrach J.D.Chief Financial Officer, Chief Bus. Officer and Sr. VP427kN/A65
Mr. David F. NovackSr. VP of Operations and Quality388.25kN/A55
Dr. Robert L. Coffman Ph.D.Chief Scientific Officer and Sr. VP468.8kN/A70
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. The company’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for the treatment of for multiple malignancies, as well as DV281 for the treatment of non-small cell lung cancer. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for varios immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Corporate Governance

Dynavax Technologies Corporation’s ISS Governance QualityScore as of June 2, 2017 is 9. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.